AFREZZA® is a rapid acting inhaled insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Insulin lowers blood glucose levels by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production.
Insulin lispro-aabc is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro-aabc is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli.
Metformin hydrochloride tablets are indicated for the management of type 2 diabetes mellitus (non-insulin dependent, NIDDM) as monotherapy when hyperglycemia cannot be managed with diet and exercise alone
Oral Anti-diabetic agents (Sulfonamides). Glibenclamide is a sulfonylurea which lowers the blood glucose concentrations by increasing sensitivity of pancreatic beta cells to glucose, resulting in stimulation of insulin release.
Metformin Hydrochloride is a biguanide antidiabetic. Glucomet® is given orally for the treatment of type 2 diabetes mellitus. Glucomet® does not stimulate insulin release and requires that some insulin be present in order to exert its antidiabetic effects.
Dextrose Injection USP is indicated in the treatment of insulin hypoglycemia (hyperinsulinism or insulin shock) to restore blood glucose levels
Diabetes mellitus (DM) is a group of metabolic disorders characterized by hyperglycemia and abnormalities in carbohydrate, fat, and protein metabolism